Clinical Review Criteria
Bone Anchored Hearing System (BAHA)

- Osseointegrated Implants
- Vibrant Soundbridge

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. Member contracts differ in their benefits. Always consult the patient's Medical Coverage Agreement or call Kaiser Permanente Customer Service to determine coverage for a specific medical service.

Criteria
For Medicare Members

<table>
<thead>
<tr>
<th>Source</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMS Coverage Manuals</td>
<td>Chapter 16, section 100 – “Hearing Aids and Auditory Implants” and section 180 – “Services Related to and Required as a Result of Services Which Are Not Covered Under Medicare.”</td>
</tr>
<tr>
<td>National Coverage Determinations (NCD)</td>
<td>None</td>
</tr>
<tr>
<td>Local Coverage Determinations (LCD)</td>
<td>None</td>
</tr>
<tr>
<td>Local Coverage Article</td>
<td>None</td>
</tr>
</tbody>
</table>

For Non-Medicare Members
Kaiser Permanente has elected to use the Hearing Aids, Bone Anchored and Bone Conduction (KP-0564) MCG* for medical necessity determinations.

*The MCG Manuals are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

<table>
<thead>
<tr>
<th>Service</th>
<th>Criteria Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vibrant Soundbridge</td>
<td>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.</td>
</tr>
</tbody>
</table>

If requesting this service, please send the following documentation to support medical necessity:
- Most recent audiogram/hearing test
- Most recent clinical notes from requesting provider &/or specialist (otolaryngology, ENT)

The following information was used in the development of this document and is provided as background only. It is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

Background
Vibrant Soundbridge System
The Vibrant Soundbridge System is an implantable alternative to standard hearing aids. It is intended for use in adults with moderate to severe sensorineural hearing loss, who desire an alternative to an acoustic hearing aid. Common limitations of conventional hearing aids are acoustic feedback, sound and voice distortion, and need for frequent servicing and maintenance (FDA documents, Sterkers et al., 2003; Luetje, 2002).

The Soundbridge system consists of a middle-ear implant known as the Vibrating Ossicular Prosthesis (VORP) and an external portion, the amplification system called the Audio Processor. The Audio Processor is about 1.2 inches in diameter and designed to be worn behind or above the ear. It contains a microphone that converts environmental sound to electrical signals. These signals are delivered to the VORP, causing the Floating Mass...
Transducer (FMT), one of its components, to vibrate. The vibration manually stimulates the auditory ossicles and is perceived by the patient as sound (manufacturer's documents).

Potential adverse effects of the Vibrant Soundbridge include the usual risks of major ear surgery and a possible decrease in residual hearing (FDA documents).

The Vibrant Soundbridge has been available commercially since February 1998 in Europe and received FDA approval in the US in August 2000. The FDA recommends that patients have experience with appropriately fitting conventional hearing aids before using the Vibrant Soundbridge.

**Bone Anchored Hearing Aid (BAHA) (Entific Medical Systems)**

The BAHA is an alternative device for hearing-impaired patients who are unable to wear traditional hearing aids. According to the manufacturer, the BAHA can be beneficial to individuals with chronic inflammation or infection of the ear canal, an incomplete ear canal e.g. congenital ear malformation and single-sided hearing loss. The BAHA is based on bone conduction technology, sound transmission without involvement of the skin and soft tissue and thus can be used by individuals with an impaired or diseased external or middle ear (Tjellstrom & Hakansson, 1995).

The BAHA device consists of an implant and an external sound processor attached to a subcutaneous abutment. The implant, a titanium fixture, is implanted behind the ear where it “osseointegrates” or bonds with the living bone. After healing from surgery, a percutaneous abutment is attached to the fixture. The sound processor “snaps” into the abutment. The sound processor, which transmits sound directly via the bone to the inner ear can be connected and disconnected at will (FDA and manufacturer’s documents).

The BAHA was developed in Sweden in the 1980s. It was approved by the FDA in August 1996 and was introduced in the US market in January 1997. There are several different models, all of which were considered by the FDA to be Class II devices, substantially equivalent to air conduction hearing aids with digital sound processing.

**Medical Technology Assessment Committee (MTAC)**

**Vibrant Soundbridge**

06/06/2005: MTAC REVIEW

**Evidence Conclusion:** There are studies with pre- and post-implantation data, but no controlled studies on the efficacy of either the Vibrant Soundbridge or the BAHA. Data from case series suggest that patients who meet eligibility requirements may experience improvement and hearing from the Vibrant Soundbridge and BAHA. Lack of blinding and lack of a control group limit the validity of case series. The publications are further limited by small sample sizes and/or missing data.

**Articles:** Vibrant Soundbridge: Only case series were identified. Most were conducted in Europe where there is longer experience with the device compared to the U.S. Two studies were selected for review: The largest case series, a French study (n=125), and the strongest US study (n=54). The US study was the one used by the FDA to grant approval. BAHA: Only case series were identified, all with sample sizes <100. The two best-case series were reviewed. They were selected based on sample size and length of follow-up. There were two publications on one of the studies, so a total of three articles were reviewed. The studies that were critically appraised are: Sterkers O, Boucarra D, Labassi S. A middle ear implant, the Symphonix Vibrant Soundbridge: Retrospective study of the first 125 patients implanted in France. Otol Neurotol 2003; 24: 427-436. See Evidence Table Luetje CM, Brackman D, Balkany TJ et al. Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: A prospective controlled multicenter study. See Evidence Table Mylanus EA, van der Pouw KC, Snik AFM et al. Intraindividual comparison of the bone-anchored hearing aid and air-conduction hearing aids. Arch Otolaryngol Head Neck Surg 1998; 124: 271-276. See Evidence Table Hol MKS, Snik AFM, Mylanus EAM et al. Long-term results of bone-anchored hearing aid recipients who had previously used air-conduction hearing aids. Arch Otolaryngol Head Neck Surg 2005; 131: 321-325. See Evidence Table Lustig LR, Arts A, Brackmann DE. Hearing rehabilitation using the BAHA bone-anchored hearing aid: Results in 40 patients. Otol Neurotol 2001; 22: 328-334. See Evidence Table

The use of Vibrant Soundbridge or the BAHA in the treatment of hearing loss does not meet the Kaiser Permanente Medical Technology Assessment Criteria.
### Criteria | Codes | Revision History

<table>
<thead>
<tr>
<th>Created</th>
<th>Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/06/2005</td>
<td>10/01/2013</td>
</tr>
</tbody>
</table>

- **MDCRPC** Medical Director Clinical Review and Policy Committee
- **MPC** Medical Policy Committee

### Codes

- **BAHA:** 69710, 69711, L8690, L8692
- **Vibrant Soundbridge:** S2230, V5095